CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
RBC Capital analyst Luca Issi lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $60.00 (from $66.00) while maintaining a Sector Perform rating.
The analyst comments "Casgevy’s launch is under way with >35 ATCs activated (vs >25 last Q) and cells collected from 20 patients (vs 5 last Q). In oncology, first look at next-gen CD19 for NHL is expected later this year. In autoimmune, lupus trial is now open. On in vivo, ANG3 and Lpa are in Phase I. Overall, we appreciate all the progress, but we remain on the sidelines, as we are cautious on Casgevy’s launch and awaiting further progress on the rest of the pipeline. We lower the PT from $66 to $60 to reflect the Q."